Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Why Pure Storage Stock Was a Big Winner on Wednesday: https://g.foolcdn.com/editorial/images/760099/finger-about-to-press-a-green-dollar-sign-key-on-a-pc-keyboard.jpg
Why Pure Storage Stock Was a Big Winner on Wednesday

Niche tech stock Pure Storage (NYSE: PSTG) had a fine Wednesday on the market, with its shares racing nearly 5% higher in value. By contrast, the S&P 500 index slumped by 0.8%. Investors were

EQS-News: Evotec announces CEO transition: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec announces CEO transition
EQS-News: Evotec announces CEO transition
EQS-Adhoc: Evotec announces CEO transition: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-Adhoc: Evotec announces CEO transition
EQS-Adhoc: Evotec announces CEO transition
Could Abbott Laboratories Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/759413/elderly-person-sitting-on-a-bed.jpg
Could Abbott Laboratories Stock Help You Become a Millionaire?

Abbott Laboratories (NYSE: ABT) is a longtime leader in the healthcare industry. The medical device specialist has been around for decades, delivering solid returns to its loyal shareholders

1 Concerning Trend for AbbVie Investors to Keep an Eye On: https://g.foolcdn.com/editorial/images/759502/worried-investor-looking-at-their-laptop.jpg
1 Concerning Trend for AbbVie Investors to Keep an Eye On

AbbVie (NYSE: ABBV) is a top pharmaceutical company with a broad mix of products in its portfolio. It also pays an attractive dividend, which yields 4% -- that's more than twice the S&P 500 average

2 Biotechs That Could Get Bought Out in 2024: https://g.foolcdn.com/editorial/images/759923/ma.jpg
2 Biotechs That Could Get Bought Out in 2024

Big pharma is facing another round of major patent expirations. Before the decade's end, Bristol Myers Squibb (BMS) will lose exclusivity for the megablockbuster blood thinner Eliquis as well as its

3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years: https://g.foolcdn.com/editorial/images/759497/investor-pointing-at-a-chart.jpg
3 Stocks That Have Turned $50,000 Into More Than $500,000 in Just 5 Years

Growth stocks get the designation because they have the potential to generate life-changing gains for investors. Some even do so in a relatively short time frame. Finding proper growth stocks

2 Biotech Stocks You Can Buy and Hold for the Next Decade: https://g.foolcdn.com/editorial/images/758457/patient-talking-with-a-physician.jpg
2 Biotech Stocks You Can Buy and Hold for the Next Decade

There are many ways to grow one's wealth over a decade, but few are as accessible as investing in stocks. Even with a relatively modest sum, picking the right investments and letting time and

3 Top Dividend Growth Stocks to Buy in 2024: https://g.foolcdn.com/editorial/images/759630/hands-behind-head.jpg
3 Top Dividend Growth Stocks to Buy in 2024

Dividends are nice. But do you know what's even nicer? Fast-growing dividends. That's especially true with inflation eroding the purchasing power of your money.

The good news for income investors is

Why Eli Lilly Stock Could Start Off 2024 With a Bang: https://g.foolcdn.com/editorial/images/759509/businessperson-giving-a-presentation.jpg
Why Eli Lilly Stock Could Start Off 2024 With a Bang

Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years. The company is now the most valuable healthcare company in the world, with a valuation of around $550

Why Eli Lilly Stock Could Start Off 2024 With a Bang: https://g.foolcdn.com/editorial/images/759509/businessperson-giving-a-presentation.jpg
Why Eli Lilly Stock Could Start Off 2024 With a Bang

Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years. The company is now the most valuable healthcare company in the world, with a valuation of around $550

Why Eli Lilly Stock Could Start Off 2024 With a Bang: https://g.foolcdn.com/editorial/images/759509/businessperson-giving-a-presentation.jpg
Why Eli Lilly Stock Could Start Off 2024 With a Bang

Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years. The company is now the most valuable healthcare company in the world, with a valuation of around $550

Prediction: These 3 Stocks Will Soar in 2024: https://g.foolcdn.com/editorial/images/759462/cheering-person-with-laptop.jpg
Prediction: These 3 Stocks Will Soar in 2024

No person knows for sure what the future will hold for stocks in the new year. However, it can be fun to attempt to predict what might happen.

Three Fool.com contributors have done just that. Here's

Got $1,500? You Can Confidently Add These 3 Stocks to Your Portfolio: https://g.foolcdn.com/editorial/images/759353/photo-of-las-vegas-strip.jpg
Got $1,500? You Can Confidently Add These 3 Stocks to Your Portfolio

Inflation is arguably the top economic story of the last couple of years. Indeed, consumer purchasing power is down 16% since the beginning of 2020. That means $1,500 would only buy $1,260 worth of

2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics: https://g.foolcdn.com/editorial/images/759577/scientist-researcher-microscope-lab.jpg
2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics

With the launch of its first gene therapy that's near-curative for sickle cell disease (SCD), everyone's talking about CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex

2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics: https://g.foolcdn.com/editorial/images/759577/scientist-researcher-microscope-lab.jpg
2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics

With the launch of its first gene therapy that's near-curative for sickle cell disease (SCD), everyone's talking about CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex

2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics: https://g.foolcdn.com/editorial/images/759577/scientist-researcher-microscope-lab.jpg
2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics

With the launch of its first gene therapy that's near-curative for sickle cell disease (SCD), everyone's talking about CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex

4 Incredible Dividend Stocks Yielding 4%-Plus to Buy in 2024: https://g.foolcdn.com/editorial/images/759627/cash-money-hundred-dollar-bills.jpg
4 Incredible Dividend Stocks Yielding 4%-Plus to Buy in 2024

Dividend stocks can be incredible investments. They've historically outperformed the market over the long term. The best returns have come from companies that routinely increase their dividends.

Is Medtronic's High-Yielding Dividend in Danger?: https://g.foolcdn.com/editorial/images/759498/people-looking-at-a-chart-on-a-laptop.jpg
Is Medtronic's High-Yielding Dividend in Danger?

High-yielding dividend stocks can make for great investments because they allow you to earn a lot more in dividends than you would with the average stock.

Today, the average dividend yield for an

3 Stocks That Could Be Monster Winners in 2024: https://g.foolcdn.com/editorial/images/759574/chart-asian-woman-pointing.jpg
3 Stocks That Could Be Monster Winners in 2024

Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task.

Three Motley Fool contributors think

3 Stocks That Could Be Monster Winners in 2024: https://g.foolcdn.com/editorial/images/759574/chart-asian-woman-pointing.jpg
3 Stocks That Could Be Monster Winners in 2024

Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task.

Three Motley Fool contributors think

3 Stocks That Could Be Monster Winners in 2024: https://g.foolcdn.com/editorial/images/759574/chart-asian-woman-pointing.jpg
3 Stocks That Could Be Monster Winners in 2024

Finding stocks that are huge winners is easy, in retrospect. Doing so before they take off is an entirely different story. However, it's not an impossible task.

Three Motley Fool contributors think

2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now: https://g.foolcdn.com/editorial/images/759427/investor-smiling-computer.jpg
2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now

While investors may be hoping for a full-throttled bull market to appear in the new year, some great companies with long-term competitive advantages and robust financials remain at reasonable

2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now: https://g.foolcdn.com/editorial/images/759427/investor-smiling-computer.jpg
2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now

While investors may be hoping for a full-throttled bull market to appear in the new year, some great companies with long-term competitive advantages and robust financials remain at reasonable

2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now: https://g.foolcdn.com/editorial/images/759427/investor-smiling-computer.jpg
2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now

While investors may be hoping for a full-throttled bull market to appear in the new year, some great companies with long-term competitive advantages and robust financials remain at reasonable